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Abstract: The global diarrheal disease burden for Shigella, enterotoxigenic Escherichia coli (ETEC), and
Campylobacter is estimated to be 88M, 75M, and 75M cases annually, respectively. A vaccine against
this target trio of enteric pathogens could address about one-third of diarrhea cases in children. All
three of these pathogens contribute to growth stunting and have demonstrated increasing resistance
to antimicrobial agents. Several combinations of antigens are now recognized that could be effective
for inducing protective immunity against each of the three target pathogens in a single vaccine
for oral administration or parenteral injection. The vaccine combinations proposed here would
result in a final product consistent with the World Health Organization’s (WHO) preferred product
characteristics for ETEC and Shigella vaccines, and improve the vaccine prospects for support from
Gavi, the Vaccine Alliance, and widespread uptake by low- and middle-income countries’ (LMIC)
public health stakeholders. Broadly protective antigens will enable multi-pathogen vaccines to be
efficiently developed and cost-effective. This review describes how emerging discoveries for each
pathogen component of the target trio could be used to make vaccines, which could help reduce a
major cause of poor health, reduced cognitive development, lost economic productivity, and poverty
in many parts of the world.
Keywords: multi-pathogen enteric vaccines; Shigella vaccine; ETEC vaccine; Campylobacter vaccine;
mucosal immunity; disease burden; stunting; models of disease; adjuvants
1. Introduction
The development of a vaccine against Shigella, a major cause of bacterial dysentery,
was pursued in the early part of the 20th century, and in the 1960s, new approaches to
develop genetically attenuated Shigella began [1]. Since then, numerous other enteric
pathogens have also been associated with infectious diarrhea [2–4]. With exceptions
such as cholera and rotavirus, there are still no licensed vaccines against many enteric
pathogens. This is true for Shigella and for the more newly recognized pathogens such as
enterotoxigenic Escherichia coli (ETEC) and Campylobacter jejuni, which have been identified
as major causes of enteric disease. Nevertheless, significant progress has been made
towards vaccine development for some of these pathogens, such that effective and practical
vaccines to prevent a major portion of the diarrheal disease they cause could soon be
reached. Recent advances in the vaccine pipelines for both Shigella and ETEC led the WHO
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to recently reaffirm these pathogens as priority vaccine targets and to develop preferred
product profiles (PPCs) for both vaccines. The WHO has also urged that combination
vaccine approaches be considered, as this option may improve the full public health value
proposition for these vaccines and therefore improve the prospects for more widespread
uptake in low- and middle-income countries (LMICs).
2. Shigella, ETEC and Campylobacter: Targets for Vaccine Development
The Institute for Health Metrics and Evaluation (IHME) estimates demonstrate that
Campylobacter, Shigella, and ETEC, in spite of regional variations in distribution [5], account
for one third of the global diarrheal disease burden with estimates of 88M, 75M, and 75M
cases annually, respectively (Figure 1) [5–7]. According to the IHME estimates, Shigella
accounts for the highest percentage of deaths among enteric bacterial pathogens (14%),
followed by Campylobacter (9%) and ETEC (4%). In addition to acute diarrheal disease,
infections with these three pathogens are also associated with both physical and intellectual
stunting in children as well as other long-term sequelae of enteric infection, including
reactive arthritis, Guillain-Barre Syndrome, and an increased risk of mortality due to other
infectious diseases in stunted children [8–10]. These three pathogens are also designated
as antimicrobial resistance threats by the WHO; therefore, vaccine development is being
prioritized for all three pathogens [11,12]. A vaccine against this target trio of enteric
pathogens could address about one-third of diarrhea cases in children. Rotavirus accounts
for another third. The final third of diarrheal cases may include members the target trio
not identified or other organisms for which no vaccine candidates are on the horizon.
Microorganisms 2021, 9, x FOR PEER REVIEW 2 of 24 
 
 
Recent advances in the vaccine pipelines for both Shigella and ETEC led the WHO to re-
cently reaffirm these pathogens as priority vaccine targets and to develop preferred prod-
uct profiles (PPCs) for both vaccines. The WHO has also urged that combinatio  vaccine 
approaches be considered, as this option may improve the full public ealth value prop-
osition for these vaccines and therefore improve the prospects for more widespread up-
take in low- and middle-income countries (LMICs). 
2. Shigella, ETEC and Campylobacter: Targets for Vaccine Development 
The Institute for Health Metrics and Evaluation (IHME) estimates demonstrate that 
Campylobacter, Shigella, and ETEC, in spite of regional variations in distribution [5], ac-
count for one third of the global diarrheal disease burden with estimates of 88M, 75M, and 
75M cases annually, respectively (Figure 1) [5–7]. According to the IHME estimates, Shi-
gella accounts for the highest percentage of deaths among enteric bacterial pathogens 
(14%), followed by Campylobacter (9%) and ETEC (4%). In addition to acute diarrheal dis-
ease, infections with these three pathogens are also associated with both physical and in-
tellectual stunting in children as well as other long-term sequelae of enteric infection, in-
cluding reactive arthritis, Guillain-Barre Syndrome, and an increased risk of mortality due 
to other infectious diseases in stunted children [8–10]. These three pathogens are also des-
ignated as antimicrobial resistance threats by the WHO; therefore, vaccine development 
is being prioritized for all three pathogens [11,12]. A vaccine against this target trio of 
enteric pathogens could address about one-third of diarrhea cases in children. Rotavirus 
accounts for another third. The final third of diarrheal cases may include members the 
target trio not identified or other organisms for which no vaccine candidates are on the 
horizon. 
 
Figure 1. Percent of total cases of diarrheal disease caused by specific pathogens. Cholera shows as 
negligible in the chart because of the low number of cases compared with the other causes of enteric 
diseases shown. These are data for 2016 cited in [5]. 
It is possible that a tri-pathogen vaccine against Shigella, ETEC, and Campylobacter 
could be realized relatively quickly if current progress could be directed and funded to-
wards vaccines exploiting conserved antigens (see discussions under individual patho-
gens below) providing broad coverage against multiple pathogens. There is an urgency 



















Percent of total cases (1.1B)
Figure 1. Percent of total cases of diarrheal disease caused by specific pathogens. Cholera shows as negligible in the chart
because of the low number of cases compared with the other causes of enteric diseases shown. These are data for 2016 cited
in [5].
It is possible that a tri-pathoge vaccine gainst Shigella, ETEC, and Campylobacter
could be realized relatively quickly if current progress could be directed and funded to-
wards vaccines exploiting conserved antigens (see discussions under individual pathogens
below) provi ing broad coverage against multiple pathogens. There is an urgency for
availability of these vaccines in LMICs, and it is the central thrust of this review article
to consider options to develop them. In recent years, the major driver for enteric vaccine
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development has evolved from a primary focus on reducing mortality to now also factoring
in reductions in acute and more longer-term morbidity, as well as socio-economic benefits.
This approach will be more formally defined in value proposition documents that are
under development for both Shigella and ETEC. The advantage of a combination vaccine is
well established for the pentavalent Expanded Program on Immunization (EPI) vaccines
for diphtheria−tetanus−pertussis, Haemophilus influenzae type b, and hepatitis B, so a
combination vaccine targeting multiple enteric pathogens may offer similar value. This
review article describes how emerging discoveries regarding each pathogen component
of the target trio could be leveraged to make combined products that could help reduce
a major cause of poor health, mortality, reduced growth and cognitive development, lost
economic productivity, and poverty in many parts of the world.
3. Shigella Component
3.1. Serotype-Dependent Candidates
To date, Shigella vaccine research has been primarily focused on serotype-specific O
polysaccharides (O-PS), although some preclinical work has also evaluated protein antigens
that are more broadly conserved and also contribute to protection. An optimal Shigella
vaccine would protect against S. flexneri 2a, 3a, and 6, as well as S. sonnei, which together
account for over 80% of cases [13,14]. A vaccine focused only on O-PS would inherently
need to incorporate O-PS from each serotype. This number of O-PS may be reduced with
a possible increase in vaccine efficacy if more conserved antigens are exploited, which
now seems possible. For example, a core Shigella proteome microarray consisting of
over 2000 antigen targets common to all Shigella species was used to assess the serum
samples from volunteers immunized with killed, attenuated, and wild-type S. flexneri
2a [15]. These studies identified a protein type three secretion system (T3SS) signature
with antibodies against IpaB, IpaD, IpaA, IpaH, and IpaC being associated with clinical
protection. In more recent proteomic and lipopolysaccharide array analyses, antibody
levels against both S. sonnei LPS and the IpaB invasion protein were associated with a
reduced risk of developing shigellosis and a reduced disease severity score following
infection with the 53G strain [16,17]. Table 1 provides a summary of the development
status of current Shigella vaccine candidates based on conserved proteins (most subunit
candidates), serotype-specific O-antigens (glycoconjugate candidates and GMMA), or both
types of antigens (cellular candidates).
Table 1. Shigella vaccine candidates (in development or previously found efficacious).
Candidate Name [Developer] Pre Clinical Ph1 Ph2 Ph3
Inactivated cellular candidates
Truncated mutant (International Vaccine Institute (IVI), PATH) X
Trivalent Shigella whole cell (PATH, Walter Reed Army Institute of Research (WRAIR)) X
Inactivated Shigella (Hilleman Laboratories) X
Live attenuated cellular candidates
GuaBA-based live attenuated (CVD1208S; University of Maryland, Baltimore
(UMB), PATH) X
VirG-based live attenuated (WRSS1, WRSs2, WRSs3, and WRSf3; WRAIR, PATH) X
Ty21a typhoid vaccine expressing Shigella LPS (Protein Potential) X
ShigETEC (Eveliqure) X
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Table 1. Cont.
Candidate Name [Developer] Pre Clinical Ph1 Ph2 Ph3
Glycoconjugate candidates
Chemically prepared glycoconjugate (National Institute of Child Health and
Human Development) X
Recombinant glycoconjugate (LimmaTech) X
Synthetic glycoconjugate (Institut Pasteur) X
Subunit candidates
InvaplexAR-DETOX (WRAIR, PATH) X
Generalized Module for Membrane Antigens (GMMA; GSK Vaccine Institute for
Global Health) X
Outer Membrane Vesicles (OMV; University of Navarra) X
Ipa DB Fusion (PATH, University of Kansas) X
IpaB—GroEL fusion (Defense Inst. of Physiology and Allied Sciences) X
34kDa OMP (National Institute of Cholera and Enteric Diseases) X
Approaches involving pathogen attenuation have historically dominated the field for
Shigella vaccine candidates. Two current attenuation strategies for Shigella are a VirG-based
mutant [18] and a guaBA-based mutant [19]. Further attenuation of these organisms was
obtained through the deletion of Shigella enterotoxins 1 and 2 (ShET1 and ShET2). These
newer attenuated Shigella vaccine candidates induce robust immune responses and have
a safety profile superior to those seen with previous constructs [18,19]. A modification
of the live attenuated Shigella strategy has been the use of the typhoid vaccine Ty21a as
a vector for the major Shigella O-PS [20,21]. This vector has been made more stable than
earlier versions and has been protective in animal models [20].
In contrast with attenuation, immunization with inactivated Shigellae has received
little attention. The safety and ease of formulation of cellular Shigella vaccines may be
further improved by the use of inactivated whole cell vaccines. This approach has been
protective in animals [22], and inactivated S. sonnei and S. flexneri 2a vaccine prototypes
were safe and immunogenic in Phase 1 trials [23,24]. As with the attenuated strategies
described above, the inactivated whole cell approach relies on including strains to cover
the major O-PS antigens, although responses to conserved antigens would also be present.
Extensive research has been conducted on subcellular approaches involving the in-
tramuscular administration of O-PS conjugated to protein carriers. Shigella conjugate
vaccines are safe and protective in adults and older children, but one prior conjugate
has been shown to not be protective in children less than 3 years of age [25]. Recently, a
recombinantly produced glycoconjugate candidate was tested in a Phase 2b clinical trial in
adults that demonstrated moderate protection against more severe shigellosis following
challenge [26–28]. A conjugate generated through a carbohydrate chemical synthesis ap-
proach is also in early clinical studies [29,30]. Whether the immunogenicity and protection
reported with conjugates in adults are due to boosting previous mucosal exposure to
the O-PS antigen or to the initiation of a predominantly systemic response remains to be
determined. Hartman [31] found that reductions in severity following immunization with
a conjugate vaccine from that seen with nonvaccinated animals were only obtained in cases
when the vaccine regimen contained a priming mucosal immunization with EcSf2a-2, a live
attenuated Shigella vaccine candidate [31]. When a parenterally administered S. flexneri 2a
O-antigen conjugate vaccine was given alone, infection severity was essentially identical to
that seen in the nonimmunized control animals. In a similar vaccine approach to the O-PS
conjugates, outer membrane vesicles of Shigella generated by the Generalized Modules
for Membrane Antigens (GMMA) approach are being developed as O-PS vaccines [32,33].
The double-mutant heat-labile toxin (dmLT) adjuvant given parenterally helps direct a
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mucosal response as well as the systemic immunity ordinarily obtained by this route [34].
This property of dmLT may benefit the immunogenicity of the conjugate vaccines, GMMA,
and other parenterally administered vaccines. In addition, recent Phase 1 and preclinical
studies indicate that dmLT can improve the serum and mucosal antibody responses to LPS
antigens, which might further enhance its benefit for candidate Shigella vaccines [35].
3.2. Serotype-Independent Candidates
In addition to O-PS-based vaccines, work is underway to exploit conserved virulence
proteins that may provide broad serotype-independent coverage against Shigella. T3SS
proteins involved in cellular invasion have shown broad protection in animals. For example,
invasion plasmid antigen (Ipa) proteins such as IpaB and IpaD have protected mice against
lethal challenge from multiple serotypes of Shigella [36–39].
The invasion complex or Invaplex is an example of a subunit vaccine that is a partially
serotype independent approach that incorporates the serotype specific LPS into a macro-
molecular complex with broadly conserved Ipa proteins. First-generation Invaplex vaccine
candidates were isolated from water extracts of virulent shigellae [40,41] and were shown
to be safe and immunogenic in clinical studies [42,43]. In an effort to increase immuno-
genicity, refine the manufacturing process, and further optimize the concept, efforts have
focused on the development of an artificial Invaplex product, with the complex assembled
from recombinant IpaB, IpaC, and purified LPS [44]. Further refinements of the Invaplex
product, which utilize LPS with under-acylated Lipid A, have shown robust immuno-
genicity and efficacy in several preclinical models when delivered intramuscularly [45].
More importantly, the artificial detoxified Invaplex (Invaplex AR-Detox) vaccine candidate
delivered intramuscularly without an adjuvant has been shown to be safe, well-tolerated,
and highly immunogenic in a recently completed Phase 1 clinical study (NCT03869333),
justifying the further evaluation of this approach. The vaccine induced serum antibody
responses directed to the three major vaccine constituents (LPS, IpaB, and IpaC) in 80–100%
of subjects across the three dose cohorts (2.5, 10, and 25 µg). Moreover, the serological
responses were found to be highly functional, with bactericidal responses that exceeded
those induced after experimental oral infection with S. flexneri 2a, 2457T. The preliminary re-
sults also indicate that the bactericidal activity is not limited to S. flexneri 2a, but extends to
other S. flexneri serotypes responsible for global morbidity and mortality, likely attributable
to the high levels of antibodies directed to the broadly conserved Ipa proteins. ALS IgG
and IgA titers from α4β7+ PBMC populations after immunization with InvaplexAR-DETOX
exceeded those induced after oral infection with S. sonnei, 53G or S. flexneri 2a, 2457T in
CHIM studies [16,28]. The frequency and magnitude of the mucosal immune responses
was encouraging, given the parenteral route of vaccine delivery.
A surface polypeptide (IcsP) located on the Shigella virulence plasmid harbors a
prominent cross-protective moiety, pan Shigella surface protein 1 (PSSP-1), common to
over 300 Shigella strains tested [46,47]. Mucosal administration of cholera toxin- or dmLT-
adjuvanted PSSP-1 induces broad protection in mice against experimental challenge, with
strains belonging to all major species and serotypes of Shigella [46]. This candidate proved
difficult to scale up for the preparation of clinical lots and was deprioritized.
Two novel whole cell approaches are now being pursued that seek to exploit more
conserved antigens of Shigella. One builds on the PSSP1 antigen strategy in that it involves
the unmasking of surface antigens such as PSSP1 on the whole cell by limiting the length of
polysaccharide chains synthesized to a single repeating unit. This is the Shigella Truncated
Mutant (STM), which utilizes genetically modified (∆wzy) inactivated bacteria retaining
only one repeating unit of O antigen chain on the bacterial surface [48]. The other candidate,
ShigETEC, is attenuated by the deletion of the T3SS and is engineered to not express any
LPS-O antigens through a targeted deletion of the rfbF gene [49–51]. Both of these novel
approaches increase exposure of conserved outer membrane proteins and could effectively
provide a broad coverage Shigella vaccine with a single cell type. Both may provide
exposure of the PSSP1 protein, but only the STM would also retain and present potentially
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protective proteins of the T3SS. In addition, there may be other novel proteins on the
surface of these “unmasked” constructs that could contribute to protection [15].
4. ETEC Component
Most ETEC vaccine candidates currently under development use cellular or subunit-
based vaccine approaches and focus on the induction of anti-labile toxin (LT) and anti-
colonization factor/coli surface (CF/CS) antibodies (Table 2), thereby blocking adher-
ence to the intestinal lining and subsequent enterotoxicity. Cellular vaccine candidates
against ETEC have included ACE527 (live attenuated) and ETVAX (inactivated whole cell).
ACE527, consisting of three ETEC strains expressing major CF and CS antigens, as well as
the B subunit of labile toxin, was significantly protective in people when co-administered
with a non-toxic double mutant of LT, dmLT, which acts as a mucosal adjuvant and an
antigen (see Section 7.2) [52]. This candidate is not currently under active development
as an ETEC vaccine because of lack of funding. In contrast, ETVAX is undergoing active
development, having recently completed a successful clinical trial in Bangladeshi adults
and infants [53,54] and a protection trial in Finnish travelers to Benin [55]. This vaccine
consists of four E. coli preparations engineered to express large quantities of the major
clinically relevant colonization factors (CFA/I) and coli surface proteins designated CS3,
CS5, or CS6. It is formulated with the B subunit of the cholera toxin modified to have
stronger homology with the ETEC labile toxin [56]. The vaccine is co-administered with
dmLT as an adjuvant.
Table 2. Enterotoxigenic Escherichia coli (ETEC) vaccine candidates (in development or previously found efficacious).
Candidate Name (Developer) PreClinical Ph1 Ph2 Ph3
Inactivated cellular candidates
ETVAX inactivated (Scandinavian Biopharma, University of Gothenburg, PATH) X
STM (IVI, University of Georgia (UGA), PATH, Washington University (WASHU),
WRAIR) X
Live attenuated cellular candidates
ACE527 live attenuated (PATH; National Vaccine and Serum Institute, UGA) X
ShigETEC (Eveliqure) X
CVD GuaBA Shigella−ETEC hybrid (UMB, Emergent) X
Ty21a expressing Shigella LPS and MEFA (Protein Potential) X
Subunit and toxin candidates
FTA (PATH, Naval Medical Research Center (NMRC), Sanofi, IDRI) X
MEFA (Kansas State University, John Hopkins University, PATH) X
LT/ST Fusion/conjugate (ENTVAC Consortium, PATH) X
dmLT mucosal adjuvant and antigen (PATH, Tulane) X
Flagellin, EtpA, EatA, EaeH, and YghJ (WASHU) X
A vaccine consisting of four strains of Shigella attenuated by deletion in the guaBA 196
operon (see above under Shigella component) wasconstructed as a Shigella-ETEC bivalent
hybrid vaccine expressing major CFA/ICS antigens of ETEC, along with labile toxin B
subunit (LTB) and a stable toxin (ST) toxoid [57]. A prototype of this vaccine, CVD1208S-
122, was recently tested in an antibiotic treated mouse model and protection against disease
was seen following oral challenge with ETEC or Shigella [58].
ShigETEC, the O-PS free Shigella vaccine construct described above, could also be a
combined Shigella−ETEC vaccine, as it has been engineered to express toxin antigens for
the LT and stable toxin (ST) of ETEC [49–51]. However, instead of CFA/I-CS antigens, this
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candidate relies on the homology between Shigella and ETEC surface proteins. Shigella and
ETEC are phylogenetically related and share a 70% nucleotide similarity [59,60]. Whether
the homology between the two organisms will be sufficient with antitoxin immunity
against all major clinical strains of ETEC is unknown. However, some data reported by
Medeiros et al. [58] indicate that at least some protection against ETEC is obtained with
the CVD1208S strain not expressing CFs, suggesting some level of conserved protection in
mice from Shigella antigens.
Other ETEC vaccine candidates based on subunit CFA/I-CS antigens, toxins, or novel
antigens are also under development, as follows:
1. Immunity against CFA/I-CS antigens could block pathogenesis by interrupting the
adhesion of the pathogen to the intestinal epithelium. An innovative, subunit ETEC
candidate uses recombinantly produced conserved subunits of some CFA/I-CS pro-
teins. These are the fimbrial tip adhesin (FTA) proteins from ETEC, which can induce
strong immune responses at systemic and mucosal sites when co-administered in-
tramuscularly with dmLT [61]. Individual FTA antigens, which would comprise a
complete quadrivalent vaccine, have each protected non-human primates [62,63]
vaccinated intramuscularly and challenged orally. Two of the FTA antigens have
undergone Phase 1 evaluations. The first is CfaE, which was found to safe and
immunogenic when given intradermally with mLT, and reduced the incidence and
severity of disease following challenge with a CFA/I-expressing ETEC [55]. The in-
clusion of the mLT adjuvant in the vaccine significantly improved the serum IgA and
IgG response to CfaE, as well as the HAI antibody response to CfaE adhesin [55,64].
The safety and immunogenicity of the CssBA (CS6) antigen with or without dmLT
given intramuscularly have also recently been evaluated in a Phase 1 trial. The CssBA
antigen was found to be safe up to a dose of 45 ug (highest dose tested), and the serum
and mucosal antibody responses to the antigen were significantly improved by the
addition of dmLT, including increased levels of anti-CS6 α4β7 cells in the peripheral
blood and anti-CS6 fecal antibody levels [65,66].
2. Multiple epitope fusion antigens (MEFA) utilize CFA/I as a platform to express the
dominant epitopes of other CFAs in a single protein, along with non-toxic LTA-LTB
and ST [67,68]. MEFA vaccines stimulate neutralizing antibodies against the selected
virulence antigens and piglets immunized with the MEFA–K88ac vaccine remained
healthy following challenge [69,70]. Quantitative culture of the piglet ileum showed
reduced colonization following immunization and K88 challenge. This candidate also
protects rabbits against colonization by a human ETEC strain (ETEC strain B7A) [71]
and could be cloned into a vector or delivered parenterally as a purified subunit.
3. The application of new “Omics” technologies and other gene-based approaches
also offer great promise for yielding new vaccine antigens from ETEC that may
provide broad protection, as well as to facilitate combined vaccine strategies [72–74].
Pangenome analysis of multiple strains, combined with open-aperture ETEC immuno-
proteome interrogation of samples from both human volunteers [72] and naturally
infected hosts, indicate that there are relatively few, highly conserved, strongly im-
munogenic, and ETEC pathovar specific antigens. These studies have highlighted
two antigens, EatA and EtpA. EtpA is an extracellular adhesin of ETEC that promotes
bacterial attachment and toxin delivery [73], acting as a bridge between bacteria
and human A blood group expressed on the intestinal epithelia [74]. Similar to
EatA, vaccination with EtpA effectively reduces the intestinal colonization of mice
by ETEC. An additional antigen and virulence factor found in ETEC, as well as in
other diarrheagenic and extra-intestinal E. coli, is YghJ (sometimes designated SslE).
This protein antigen has shown protection in animal models, suggesting that it may
have a vaccine potential [75–78]. The inclusion of these non-canonical antigens in
ETEC vaccine candidates could complement or broaden the protection afforded by
CF-based antigens. The majority of ETEC strains express a mucin-degrading serine
protease autotransporter protein known as EatA [79], and EatA expression was re-
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cently shown to correlate strongly with symptomatic infection among young children
in Bangladesh [80]. SepA, discovered as the major secreted protein present in culture
supernatants of S. flexneri 5a [81], is an orthologue of EatA with which it shares a
~75% amino acid identity. Surveys of Shigella genomes reveal the presence of either
SepA or EatA genes in each Shigella species [82], with SepA predominating in flexneri,
and EatA more commonly represented in S. sonnei. The secreted EatA passenger
domain is strongly immunogenic following ETEC infection of humans [83], and vacci-
nation with this domain reduces colonization of mice after challenge with ETEC [72].
Whether vaccination with EatA or SepA can afford cross protection against ETEC and
Shigella in humans remains to be determined.
4. The virulence of ETEC strains is associated with LT and ST enterotoxins expressed
in the small intestine. Toxoids based on the LT or ST antigens may be found to
contribute to the effectiveness of ETEC vaccines. A transdermal LT patch, no longer
in development, was used to show protection against LT-only producing strains in a
Phase 3 trial [84]. dmLT has also been shown to induce anti-LT antibody responses in
human volunteers and to induce better LT toxin neutralization antibody responses
than when B-subunit toxoid preparations have been used [85]. Field and controlled
human infection model (CHIM) study data indicate that inducing anti-LT immunity
can be an immune marker for reduced risk of ETEC illness, particularly as a result
of the ETEC strains expressing only the LT toxin [84,86]. CHIM and field studies
also indicate that strong immune responses to LT can help to reduce the severity of
ETEC illness when it occurs [84,87]. LT appears to promote ETEC colonization by
changing the surface architecture of the intestinal epithelia to favor the pathogen
attachment [88], and anti-LT immunity can cooperatively impact effective ETEC small
intestinal colonization when combined with anti-adhesin approaches [73]. Moreover,
LT has been shown to accentuate the enterotoxic effects of the ST toxin [89], suggesting
that anti-LT immunity could be beneficial in mitigating the impact of both toxins.
The importance of ST in a vaccine is less well established, but passive immunization
studies in piglets have shown protection against disease [70]. Recent work has shown
that the ST molecule can be detoxified without losing neutralizing properties, be made
immunogenic by linking to a protein, and avoid cross reaction with human guanylin-
uroguanylin [90–92]. In addition, novel studies of ST toxin secretion and delivery
have shown that the STH propeptide is secreted by ETEC, potentially providing
additional epitopes for inducing toxin neutralizing antibodies [93]. These studies also
showed that EtpA adhesin plays an important role in ST toxin delivery to intestinal
epithelial cells, suggesting that antibodies against this potential vaccine antigen could
reduce ST toxicity [93].
5. Campylobacter Component
Several antigens of Campylobacter have been considered for vaccines, yet few candi-
dates for C. jejuni vaccines are currently under development (Table 3) [94]. A prototype
monovalent capsular polysaccharide (CPS) conjugate vaccine using CRM197 as the pro-
tein carrier has been evaluated in a number of preclinical studies, and was found to be
highly immunogenic in mice, and demonstrated efficacy against diarrheal disease in Ao-
tus nancymaae, a new world owl monkey species [95]. A Phase 1 first-in-human trial
(ClinicalTrials.gov Identifier: NCT02067676) was recently completed demonstrating the
safety and immunogenicity of the vaccine candidate [94]. In follow-on preclinical studies,
the immunogenicity of the prototype CPS vaccine could be improved by administering it
intramuscularly in a liposome carrier also containing MPL and QS-21. This adjuvanted
vaccine candidate was protective in the new Zn-deficient Campylobacter mouse model [96].
It is anticipated that a complete vaccine against Campylobacter based on CPS would be
multi-valent, which could raise manufacturing questions about its practicality for use in
LMICs, particularly if part of a combination vaccine.
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Table 3. Campylobacter vaccine candidates (in development or previously found efficacious).
Candidate Name [Developer] PreClinical Ph1 Ph2 Ph3
Inactivated cellular candidates
STM—heptasaccharide (IVI, PATH, UGA, and WRAIR) X
ACE527 expressing heptasaccharide (PATH, UGA, University of Alberta (UA)) X
Subunit candidates
Capsular Polysaccharide (NMRC) X
N-glycan Heptasaccharide (UGA, UA, PATH) X
Truncated flagellin FlaA-MBP (NMRC) X
B-subunit of cholera toxin (Kuwait University) X
Three approaches utilizing highly conserved antigens have been explored as candidate
vaccines for immunization against Campylobacter. One of these is flagellin [94], the immun-
odominant antigen recognized during infection with Campylobacter. Antibodies against flag-
ellin correlates with the development of protection against disease [97–101]. Early CHIM
studies demonstrated that volunteers challenged with C. jejuni strain 81–176 developed a
robust immune response against the flagella [97]. In addition, the immunological response
against the flagellin was correlated with the protection against disease during re-challenge
studies [97]. To generate a recombinant flagellin-based vaccine, the conserved region of
FlaA from C. coli VC167 was fused with the maltose binding protein (MBP) of E. coli. The
vaccine (rFlaA-MBP) was formulated with mLT and was tested for immunological response
and protective efficacy in a mouse colonization model. Encouraging results were obtained;
an intestinal secretory IgA response and protection against heterologous colonization and
disease by C. jejuni 81–176 were established when the rFlaA-MBP was adjuvanted with a
single mutant of LT (LTR192G). This vaccine candidate progressed through a Phase 1 trial,
but was abandoned because of poor immunogenicity, despite showing promising efficacy
in mice [97]. The human trial, in contrast with prior animal studies, did not include the
mLT adjuvant used in the mouse studies as a result of safety concerns associated with the
intranasal administration of the mLT. This candidate could be reevaluated with a different
route of administration to include an adjuvant with an established improved safety profile
such as dmLT.
The remaining two antigens are in preclinical development. One is based on the
homology between cholera toxin B subunit (CTB) and a 53 KDa major outer membrane
protein, PorA of Campylobacter. Immunization with CTB reduced the colonization of adult
mice challenged with C. jejuni [102,103]. The other approach utilizes a conserved N-glycan
heptasaccharide of Campylobacter for immunization. This antigen was displayed on E. coli to
immunize chickens and provided up to a 10-log reduction in C. jejuni colonization following
challenge [104]. This effect was also obtained in chickens with a the heptasaccharide
conjugated to an engineered N-glycan carrier protein, GlycoTag, given parenterally [104].
6. Multi-Pathogen Strategies
Protective and relatively conserved antigen candidates are certainly available for
each of the three targeted enteric pathogens, but at present, relatively little effort is being
made to consolidate them into a single multi-pathogen vaccine. Efforts made to date
have been directed towards the combination of ETEC and Shigella with the omission of
Campylobacter. The inclusion of Campylobacter with these other pathogens could improve
its value as a licensed vaccine. The consideration of combination vaccine approaches for
these major causes of morbidity and mortality among infants and young children in LMIC
settings, as well as among international travelers, have long been encouraged by donors
and international stakeholders such as WHO and Gavi [105–107]. It has only been recently
Microorganisms 2021, 9, 1382 10 of 24
that candidate antigens, adjuvants, and formulation strategies have existed that might
make the pursuit of a multi-pathogen vaccine more feasible. An additional driver for
this approach is the growing acceptance that a combination vaccine would have a more
favorable full vaccine value assessment, which would help ensure a greater potential for
wider uptake once available. In this vein, the WHO’s recent PPCs for both Shigella and
ETEC vaccines also suggested that the combination vaccine approach for these pathogens
should be explored [108].
6.1. Multi-Pathogen Vaccines for Oral Administration
The most active area for the consolidation of enteric pathogen vaccines is orally deliv-
ered whole cell vaccine candidates, some of which exploit relatively conserved antigens
in addition to serotype-specific immunity. The utilization of oral immunization avoids
possible problems associated with the multiple use of needles on a crowded EPI schedule in
LMICs, as needed for parenteral administration [109]. The oral route could also avoid the
challenge of having all of the components co-formulated in a single container for licensure,
which could be associated with subunit injectable vaccines if developed independently, as
oral vaccine can be co-administered rather than co-formulated, although the latter would
be ideal and would benefit the full value proposition for the vaccine. On the other hand,
the reduced efficacy of orally administered vaccines in LMIC settings compared with
high-income countries has been clearly documented for rotavirus and cholera vaccines;
therefore, applying this approach for an oral vaccine should be done cautiously and with
a detailed plan to evaluate the interference between antigens (or vaccines) and mucosal
immune responses. Recent evidence in Bangladeshi children given the oral whole cell
vaccine, ETVAX, indicate that the inclusion of the mucosal adjuvant dmLT may improve
immune responsiveness to orally administered vaccines [54].
Multi-pathogen cellular approaches are now being developed, most using an attenu-
ated oral Shigella cellular vaccine candidate as a platform (Table 4).
Table 4. Multi-pathogen vaccine candidates.
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Table 4. Cont.
Route of Administration Current Description Status Possible Added PathogenAntigens
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1. The guaBA Shigella−ETEC hybrid 1208-122 should provide effective coverage against
both Shigella and ETEC, relying on antigens that have been well established to pro-
tect [57]. A prototype of this candidate, S. flexneri 2a expressing CFA/I and LT,
protected orally challenged mice against ETEC and Shigella [58], and may enter
Phase 1 evaluation in 2021 (https://clinicaltrials.gov/ct2/show/NCT04634513, ac-
cessed on 1 May 2021). This approach demonstrates the use of expression of het-
erologous antigens to broaden coverage, which could also be applied to conserved
Campylobacter antigens.
2. ShigETEC, in contrast with the hybrid, relies entirely on little studied but promis-
ing conserved surface proteins minus those of the deleted T3SS to protect against
Shigella [49,50]. The strain contains a RfbF deletion that renders it rough, i.e., not
expressing the serotype-determining O-PS. ETEC coverage is anticipated from homol-
ogy existing between Shigella and ETEC [59,60], as well as the LT/ST chimeric toxoid
expressed [51]. As stated above, the extent that the homology present in Shigella will
contribute to protection against major ETEC strains remains to be determined.
3. A third platform at an earlier stage of development than the previous two is the
Shigella truncated mutant (STM) comprised of inactivated Shigella mutants with O-
polysaccharide chains truncated to one repeating unit in length [48]. This, like the
ShigETEC, enhances the immunological accessibility of conserved and protective
Shigella outer membrane proteins such as PSSP-1 [46], and may also be a benefit
to vectored antigens. STM also express additional conserved proteins not normally
masked by O-polysaccharide chains, such as the Ipa proteins (deleted in the ShigETEC
approach), which could also contribute to broader serotype-independent immu-
nity [36,37]. STM should also benefit from homology to ETEC, but it remains to be
seen whether it may also be necessary to engineer the expression of some additional
ETEC antigens such as EtpA or CS6 into the STM for optimal coverage. For instance,
data emerging from the analysis of more than 1500 phylogenetically and geographi-
cally diverse isolates of ETEC suggest that a combination of CS6 and EtpA, which is
more frequently absent in CS6-expressing strains, would afford coverage for more
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than 80% of ETEC [65,72]. The STM is the only candidate currently planned to be
engineered to express the conserved Campylobacter heptasaccharide [104].
4. A recombinant live oral ETEC vaccine (Ty21a-ETEC) composed of Ty21a, the oral
typhoid vaccine, expressing both heat-labile (LT) and heat stable enterotoxin (STa)
and seven adhesins (CFA/I, CFA/II (CS1-CS3), and CFA/IV (CS4-CS6)) that facilitate
the colonization of host intestines and binds GM1was constructed [110]. The seven
adhesins comprise a multi-epitope fusion antigen (MEFA) that has shown to have a
broad spectrum anti-adhesin activity. The intranasal (IN) immunization of BALB/c
mice, which mimicked a mucosal/oral route of immunization, induced antibodies
against LTB and MEFA that blocked binding to GM1, showing the induction of an anti-
toxin activity. Further antibodies induced by IN immunization induced antibodies
that blocked the adhesion of ETEC to Caco-2 cells. The typhoid vaccine has also
served as a vector for the major Shigella O-PS [20,21].
6.2. Multi-Pathogen Vaccines for Parenteral Administration
In contrast to the current activity with the cellular candidates, injectable subunit
candidates addressing multiple enteric pathogens have been minimally pursued. Currently,
the promising subunit vaccine candidates described above are being developed as single
pathogen products that could add a likely unacceptable number of injections to an already
crowded immunization schedule. If developed separately, consolidation could be a long
and expensive process. On the other hand, parenteral administration of a multi-pathogen
vaccine could avoid issues with reduced vaccine efficacy in LMIC populations that have
plagued oral rotavirus and cholera vaccines and reduce the number of injections required.
Recently, one group has described a prototype for a tri-pathogen subunit conjugate vaccine
to cover Shigella, ETEC, and Campylobacter [111]. This vaccine could consist of eight C. jejuni
CPS, four Shigella O-PS, and four to five ETEC adhesin proteins. This approach is intriguing;
however, valency requirements may be problematic. A more efficient strategy could be
to exploit the more broadly conserved C. jejuni antigens (e.g., heptasaccharide or FlaA);
however, questions remain regarding their potential to serve as human vaccine antigens.
In addition to its potential use as a Shigella vaccine, as it is capable of inducing broad
immune responses across multiple Shigella serotypes, Invaplex has been shown to be an
effective adjuvant, augmenting the immune responses directed to co-administered protein-
or plasmid-DNA-based vaccines [112–115]. The adjuvant activity of Invaplex is attributed
to the biological activity of the complex, which facilitates the cellular uptake of Invaplex
and heterologous antigens, and the LPS component or Lipid A moiety that provides a
“danger signal” to the immune response, resulting in effective immune processing and
increased immunogenicity. Interestingly, the under-acylated Lipid A molecule utilized
in InvaplexAR-DETOX is also capable of providing a danger signal for enhanced immune
responses, albeit at lower but more controlled levels. Using ovalbumin (OVA) as a model
antigen, intranasal immunization with OVA combined with Invaplex was found to enhance
the anti-OVA serum immunoglobulin G (IgG) and IgA responses and induce OVA-specific
mucosal antibody responses at sites located both proximal and distal to the immunization
site [112]. Subsequently, the adjuvant effect of Invaplex has been demonstrated for ETEC
antigens CS3 and CS6 (Figure 2), as well as Campylobacter FlaA [115], in the absence of
immune interference. These data suggest that InvaplexAR-Detox can serve as a platform for
the delivery of heterologous antigens to be included in a multi-pathogen vaccine, while
still inducing potent immunity against shigellosis.
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Figure 2. Immune response to Shigella and ETEC CS3 antigens in a combined vaccine as shown in Figure 3. CS6 and
CFA/I in combination with dmLT or Invaplex had significantly higher anti-CS3 antibody titers compared with titers after
immunization with CS3, CS6, and CFA/I alone (Panel A). The immune response to CS6 was similarly enhanced, but the
immune response to CFA/I was unaffected. Serum IgG titers directed in Invaplex (Panel B) were co parable in guinea pigs
immunized with CS3, CS6, and CFA/I delivered alone or in combination with Invaplex, indicati g that the ETEC antigens
did not interfere with the Shigella antigen- pecific immune responses. For these unpublished data (R. K minski), Guinea
pigs (Hartley strain; six pigs/grp) were immunized intradermally on study days 1, 22, and 43 with either 6.25 µg of CFA/I,
CS3, and CS6 delivered with and without dmLT (500 ng) or Invaplex (25 µg). Blood collected on days 1, 22, 43, and 57 were
assayed by ELISA for serum IgG titers directed to CS3 (A) and Invaplex (B). Data represents the geometric mean titer and
95% confidence interval.
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7. Considerations to Optimize the Immunological and Practical Impact of Vaccine
C didates to Provide an Effective Multi-Pathogen Vaccine Str tegy
7.1. Pediatric Presentation for Oral Vaccines
While the tri-pathogen vaccine approach provides the benefit of protection against
multiple pathogens in a single vaccine formulation of multiple antigens, the antacid buffer
and, potentially, the adjuvant can be challenging. A currently licensed vaccine against
cholera (Euvichol) may serve as a model for the packaging and delivery of a tri-pathogen
vaccine. The inactivated whole cells in this vaccine are suspended in saline contained in
a flexible plastic tube that can be used to deliver the vaccine directly to the mouth. This
presentation allows for flexibility for the tri-pathogen vaccine final formulation; if, for
example, vaccine components are found to be incompatible, they can be envisioned, as
necessary, in separate flexible tubes or lyophilized in vials for co-administration (Figure 3).
A buffer, for example, could be packaged in a separate tube, minimizing the vaccine
antigens’ exposure to high osmolarity or lyophilized for an improved shelf-life of the final
product [116–119]. To accomplish this for pediatric use, a citrate buffer similar to that being
used with licensed oral rotavirus vaccines could be considered to avoid the rehydration
process associated with the use of bicarbonate buffer vaccines and provide the needed shelf
life in a liquid formulation. Similarly, for inactivated or live attenuated cells, lyophilization
offers a means to achieve better long-term stability. Using this approach, lyophilized whole
cells could be rehydrated using the liquid buffer through a modified flexible tube similar
to a pipette. Once resuspended, the same flexible tube could be used for the subsequent
administration (Figure 3).
7.2. dmLT Adjuvant
Whether an oral or intramuscular vaccine is developed, accumulating animal and
clinical data are demonstrating the importance of considering use of the adjuvant dmLT
with vaccines against mucosal pathogens. Mucosal and systemic immune responses to
both live and inactivated vaccines can be improved by adding the adjuvant dmLT, a highly
attenuated form of the ETEC heat-labile toxin (LT), to candidate vaccine formulations,
while at the same time inducing anti-LT immunity [120–122]. Accumulating data have
shown that dmLT may improve vaccine Th1/Th2/TH17 balance and enhance mucosal
aspects of immune response in order to provide better protection by novel and established
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vaccines [122–125]. In fact, new adjuvant data from 6- to 11-month-old Bangladeshi infants,
a difficult population in which to achieve robust immunity following the administration
of vaccines, show that dmLT improves the frequency and the magnitude of the mucosal
immune response to ETEC antigens following immunization with a killed whole cell vac-
cine, ETVAX [54]. Furthermore, in Bangladeshi infants, the kinetics of the mucosal immune
response were accelerated by the inclusion of dmLT in the vaccine [123]. In addition, these
studies in infants in Bangladesh have also shown that the dmLT adjuvant can improve the
mucosal antibody response to both protein and polysaccharide antigens, and that the use of
dmLT was particularly important for ETEC vaccine “take” in 6- to 11-month-old infants, as
fractional doses of the vaccine needed to be used to improve its tolerability [35]. In earlier
work, the live attenuated ETEC candidate vaccine ACE527 provided significant protection
in a Phase 2b challenge study only when the vaccine was co-administered with dmLT [52].
Recent Phase 1 studies with prototype ETEC vaccine subunit antigens have shown that
dmLT can be used safely through the intradermal and intramuscular routes, and that it can
improve the frequency and magnitude of serum and mucosal antibody responses to these
subunit ETEC vaccine antigens, CfaE and CssBA [64,66,126]. Based on results such as these,
for both oral and parenteral vaccines, it is likely that the immunogenicity of a tri-pathogen
vaccine in target populations may similarly be enhanced by the co-administration of dmLT.
7.3. Improved Tolerability and Immunogenicity of Oral Inactivated Whole Cell Vaccines for Infants
Recent clinical trials with ETVAX clearly demonstrate that safety, immunogenicity, and
protection can be obtained with inactivated whole cell vaccines [54,55]. As has been found
for the licensed inactivated cholera vaccine, Euvichol, standardization of vaccine dose for
such vaccines based on the antigen content of the cells offers more effective immunization
dosage control [127–129]. Although immunogenic, it has been found in infants that adult
doses of ETVAX can induce mild vomiting in some children within hours of administration
of an adult dose of vaccine, but fractional dosing (e.g., 1/8 to 1/4 of an adult dose) can
reduce this tolerability issue without sacrificing immunogenicity [54]. This process reduces
the levels of reactogenic LPS. Reactogenicity to LPS may, in the future, be reduced by the
insertion of an msbB mutation in the LPS of the Shigella platform to under acetylate the
lipid A of the endotoxin cell wall component [130]. A combination of pediatric doses and
the msbB mutation in an endotoxin-containing preparation could help further resolve this
tolerability issue.
7.4. Dosing Schedule
As has already been indicated, the tri-pathogen vaccination strategy is directed at
infants, the target population with the greatest need. To be accepted and practical in an
LMIC, it would be important to be able to give multiple doses of vaccine on an existing
vaccination schedule, thereby benefitting the value proposition for the vaccine. It has been
reported that oral immunization with non-living antigens such as inactivated whole cells
requires several doses to be given [131]. The gut IgA system needs this repeated exposure
to achieve the multiplication of high-affinity B cell populations in the lamina propria. It
is not known if vaccines given intramuscularly would require a similar kinetics as orally
administered vaccines. The dosing schedule is important because some components of
a multi-pathogen vaccine may be most important at different ages. Some of the target
enteric pathogens, such as Shigella, may become more problematic later in life than others.
With this in mind, a booster with the multi-pathogen vaccine at 9 months of age when the
measles vaccine is given could be considered for priming doses given earlier. Experience
with ETVAX in Swedish adults clearly indicates the possible benefit of an oral booster
dose [132].
7.5. Animal Models for Protection
Even with the progress that has been made toward the development of effective anti-
gens, moving to successful clinical development of a tri-pathogen product will benefit from
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the availability of predictive animal models of each disease for the numerous preclinical
studies required. Although some models are available, this deficiency has been a hurdle for
all three of the pathogens discussed in this review. New models have recently been reported
that may improve the situation and greatly benefit the field. There is a high probability
now that mouse models using nutrient deficiencies and/or antibiotic treatment to increase
the susceptibility of animals to enteric infections recently developed at the University of
Virginia may provide a simple and inexpensive way forward to test protection against
intestinal disease following immunization and subsequent oral challenge with either of
the three enteric pathogens of interest [133–135]. These models provide the opportunity to
test a realistic oral infection against all three pathogens in the same small animal system.
An alternate, complementary non-human primate model, Aotus nancymaae, provides a
large-animal model, that, as with mice, can be infected orally with the development of
subsequent disease manifestations from Shigella, ETEC, and Campylobacter [136–138].
7.6. CHIMs for Enteric Vaccine Development
The importance of CHIM studies for enteric pathogens has been clearly established
by the experience with typhoid and cholera vaccines. In the case of the typhoid conjugate
vaccine, a positive result in a CHIM study of healthy British adults was critical in augment-
ing Phase 3 field-study data for endemic countries such as Nepal [139–141]. The cholera
vaccine Vaxchora® was the first vaccine licensed by the US Food and Drug Administration,
primarily on the basis of efficacy in a CHIM study [142]. However, Vaxchora was approved
for travelers to cholera-endemic regions and additional data iares needed to establish its
efficacy in LMIC residents.
CHIMs have been established for all three target pathogens [52,143–145]. CHIM
studies have the potential to play a crucial role in the testing of vaccine candidates for these
three pathogens for downselection and de-risking advancement to expensive Phase 3 field
studies. The Shigella CHIM has a key role to play in the development of vaccines to prevent
shigellosis. Several of the most advanced candidates have been tested in CHIM studies,
including Flexyn2a [143] and GSK3536852A [144]. The results of these trials are drivers of
the decisions of whether to advance one of these candidates to Phase 3 field studies. Nearly
all Shigella CHIM studies have been conducted in US volunteers that presumably had little
to no previous natural exposure to Shigella, and in some cases were pre-screened to ensure
they were immunologically naïve. To address this potential limitation in relevance, efforts
are underway to establish the Shigella CHIM in a low-income country setting [146].
Like Shigella, the ETEC CHIM is also expected to play a key role in vaccine devel-
opment. The ETEC CHIM was used to demonstrate efficacy of the oral, live attenuated
ACE527 candidate adjuvanted with dmLT [52]. Alternatively, other ETEC candidates such
as ETVAX have progressed to field studies without first being tested in CHIM studies [54].
Future candidates will likely balance the comparative speed and efficiency of evaluation in
a CHIM study, with the benefit of demonstrating efficacy in a more costly and complicated
field study. For organizations or funders interested in downselecting from a portfolio of
candidates, an ETEC CHIM study may be an attractive option.
The Campylobacter CHIM has been redeveloped because of safety concerns with the
earlier 81-176 strain, which expresses ganglioside 2 and ganglioside 3, which have been epi-
demiologically linked to Guillain-Barré Syndrome [147]. The current model uses CG8421,
which has no ability to express any ganglioside mimicry [145]. In one study of 15 subjects
challenged with this organism, 93% subsequently experienced campylobacterosis. The
CG8421 CHIM also provided a high attack rate in a rifaximin prophylaxis trial [148] and in
an unpublished vaccine trial with ACE393 (NCT00859716).
8. Conclusions
Approaches to vaccines against enteric pathogens have been complicated not only by
the numerous virulence factors, serotypes, and species involved, but also by the challenge
of achieving protective immunity in the highest risk pediatric age-groups, the variety
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of vaccine formats (i.e., whole cell or subunit), and routes of administration. Several
combinations of antigens are now available that could be effective for inducing protective
immunity against each of the three highly prevalent target pathogens. The challenge is to
achieve a combination of protective antigens with relatively few components so that the
vaccine will be efficiently developed and will be cost-effective for subsequent manufacture.
The product achieved should ideally be optimal for the pediatric population initially
and should capitalize on conserved antigens effectively delivered in an LMIC setting.
Although the pediatric population is a major target for enteric vaccines, the travelers’
market may provide additional economic incentive to help drive vaccine manufacture. The
value proposition for enteric vaccines emphasizes the importance of a vaccine to cover more
than one pathogen [107,108]. Based on the state of the art presented here, it seems likely that
this can be achieved through the development of both orally and parenterally administered
candidates. However, as discussed above, a unified approach to a tri-pathogen subunit
vaccine would be valuable, justified, and feasible. Regardless of whether enteric vaccines
are for administration orally or parenterally, serious consideration should be given to the
inclusion of an adjuvant like dmLT to help promote a protective mucosal response and
provide dose sparing.
Decades have passed without obtaining licensure for vaccines against Shigella, Campy-
lobacter, or ETEC. We now have tools and knowledge not previously available. The field is
in a strong position to soon develop vaccines for Shigella and other enteric pathogens in
order to enable a successful multi-pathogen vaccination strategy. However, this goal is in
jeopardy because of the limited number of major donors in the field, but it is possible that
new donors and manufacturing partners can be found to help offset this problem. With
timely, sufficient, and sustained funding, knowledge and tools are now available to make a
multi-pathogen enteric vaccine a reality. Early involvement of a manufacturing partner in
this process should further ensure the realization of the opportunities now before us. The
benefits of a tri-pathogen enteric vaccine to those living in LMICs are too great to let the
current opportunity pass.
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